HUE056428T2 - Kristályos alakú difenilmetán-származék - Google Patents

Kristályos alakú difenilmetán-származék

Info

Publication number
HUE056428T2
HUE056428T2 HUE20152959A HUE20152959A HUE056428T2 HU E056428 T2 HUE056428 T2 HU E056428T2 HU E20152959 A HUE20152959 A HU E20152959A HU E20152959 A HUE20152959 A HU E20152959A HU E056428 T2 HUE056428 T2 HU E056428T2
Authority
HU
Hungary
Prior art keywords
crystalline form
diphenylmethane derivative
diphenylmethane
derivative
crystalline
Prior art date
Application number
HUE20152959A
Other languages
English (en)
Inventor
Hee-Kyoon Yoon
Se-Hwan Park
Ji-Sung Yoon
Soongyu Choi
Hee Jeong Seo
Eun-Jung Park
Younggyu Kong
Kwang-Seop Song
Min Ju Kim
So Ok Park
Original Assignee
Dae Woong Pharma
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma, Green Cross Corp filed Critical Dae Woong Pharma
Publication of HUE056428T2 publication Critical patent/HUE056428T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/005Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00Introduction of protecting groups or activating groups, not provided for in the preceding groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE20152959A 2016-06-17 2017-06-15 Kristályos alakú difenilmetán-származék HUE056428T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160075910 2016-06-17

Publications (1)

Publication Number Publication Date
HUE056428T2 true HUE056428T2 (hu) 2022-02-28

Family

ID=60664449

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE20152959A HUE056428T2 (hu) 2016-06-17 2017-06-15 Kristályos alakú difenilmetán-származék

Country Status (29)

Country Link
US (2) US10640496B2 (hu)
EP (2) EP3663292B1 (hu)
JP (4) JP6763978B2 (hu)
KR (2) KR102233229B1 (hu)
CN (2) CN113651803B (hu)
AU (1) AU2017285813B2 (hu)
BR (1) BR112018076243A2 (hu)
CA (2) CA3081033C (hu)
CL (1) CL2018003645A1 (hu)
CO (1) CO2018014018A2 (hu)
DK (2) DK3663292T3 (hu)
DO (1) DOP2018000287A (hu)
EC (1) ECSP19000185A (hu)
ES (2) ES2898336T3 (hu)
HR (1) HRP20211670T8 (hu)
HU (1) HUE056428T2 (hu)
MA (2) MA44545B2 (hu)
MX (2) MX2021008988A (hu)
NZ (1) NZ749398A (hu)
PE (2) PE20240590A1 (hu)
PH (1) PH12018550206A1 (hu)
PL (2) PL3663292T3 (hu)
PT (2) PT3473621T (hu)
RS (1) RS62550B1 (hu)
SA (1) SA518400666B1 (hu)
SG (2) SG11201811154QA (hu)
SI (1) SI3663292T1 (hu)
TN (1) TN2018000437A1 (hu)
WO (1) WO2017217792A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011054773A1 (de) 2011-10-25 2013-04-25 Vb Autobatterie Gmbh & Co. Kgaa Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols
MX2021001732A (es) * 2018-08-13 2021-06-23 Daewoong Pharmaceutical Co Ltd Preparacion de intermedio util para la sintesis de inhibidor de sglt.
CN112341416A (zh) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 一种制备苯并含氧脂杂环衍生物的方法
WO2021172955A1 (ko) 2020-02-27 2021-09-02 주식회사 대웅제약 Sglt 저해제의 합성에 유용한 중간체 및 이를 이용한 sglt 저해제의 제조 방법
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
US20230322699A1 (en) 2020-09-10 2023-10-12 Daewoong Pharmaceutical Co., Ltd. Synthesis method for preparing sglt inhibitor intermediate
CN113200860A (zh) * 2021-04-29 2021-08-03 爱斯特(成都)生物制药股份有限公司 一种sglt2抑制剂中间体的制备方法
CN113801010A (zh) * 2021-11-18 2021-12-17 山东诚创蓝海医药科技有限公司 一种5-溴-2-氯苯甲酸的制备方法
CN113912487B (zh) * 2021-11-23 2024-05-28 山东研峰新材料科技有限公司 一种2,5-双卤代苯甲酸的合成方法
KR20230110001A (ko) * 2022-01-14 2023-07-21 주식회사 대웅제약 Ssglt 저해제의 합성에 유용한 중간체의 제조 방법
KR20240044190A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법
KR20240044194A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
DK2896397T4 (da) * 2003-08-01 2020-11-16 Mitsubishi Tanabe Pharma Corp Nye forbindelser med hæmmende aktivitet mod natriumafhængig glukosetransportør
EP2183263B1 (en) 2007-07-26 2011-10-26 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
AR075262A1 (es) 2008-07-30 2011-03-23 Ferrer Int Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno, proceso para prepararlos, composicion farmaceutica que los comprende, sus usos como medicamentos, o en tratamientos o prevenciones de condiciones asociadas con un funcionamiento alterado de los sistemas regulados por la melatonina, sus usos para
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
US9034921B2 (en) * 2011-06-01 2015-05-19 Green Cross Corporation Diphenylmethane derivatives as SGLT2 inhibitors
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
FR3017868A1 (fr) * 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
SA518400666B1 (ar) 2021-11-30
ES2891825T3 (es) 2022-01-31
MA50774A1 (fr) 2021-03-31
DK3473621T3 (da) 2021-09-06
ES2898336T3 (es) 2022-03-07
JP2023145481A (ja) 2023-10-11
MA50774B1 (fr) 2022-02-28
US10889574B2 (en) 2021-01-12
CL2018003645A1 (es) 2019-03-22
AU2017285813B2 (en) 2020-02-06
RU2021129636A (ru) 2021-11-22
ECSP19000185A (es) 2019-01-31
PE20240590A1 (es) 2024-03-21
CA3026756A1 (en) 2017-12-21
SI3663292T1 (sl) 2022-01-31
MX2018015647A (es) 2019-04-11
HRP20211670T8 (hr) 2022-03-18
PL3663292T3 (pl) 2022-01-17
KR20210036892A (ko) 2021-04-05
WO2017217792A1 (ko) 2017-12-21
US20190169174A1 (en) 2019-06-06
JP7352509B2 (ja) 2023-09-28
MA44545A1 (fr) 2019-10-31
EP3663292A1 (en) 2020-06-10
NZ749398A (en) 2020-01-31
US10640496B2 (en) 2020-05-05
CN113651803A (zh) 2021-11-16
JP2021152054A (ja) 2021-09-30
CO2018014018A2 (es) 2019-03-08
TN2018000437A1 (en) 2020-06-15
MA44545B2 (fr) 2020-11-30
RU2019101056A3 (hu) 2020-07-17
MA44545B1 (fr) 2020-05-29
DK3663292T3 (da) 2021-10-25
EP3663292B1 (en) 2021-09-01
EP3473621B1 (en) 2021-08-04
JP2020117528A (ja) 2020-08-06
KR102379584B1 (ko) 2022-03-29
KR20170142904A (ko) 2017-12-28
SG11201811154QA (en) 2019-01-30
CN109311861A (zh) 2019-02-05
JP2019521985A (ja) 2019-08-08
DOP2018000287A (es) 2019-03-31
JP6763978B2 (ja) 2020-09-30
PT3663292T (pt) 2021-11-08
PH12018550206A1 (en) 2019-09-30
KR102233229B1 (ko) 2021-03-29
CA3026756C (en) 2021-03-02
BR112018076243A2 (pt) 2019-03-26
CN113651803B (zh) 2022-10-28
EP3473621A4 (en) 2020-03-11
HRP20211670T1 (hr) 2022-02-18
CA3081033A1 (en) 2017-12-21
CA3081033C (en) 2022-04-12
US20190382390A1 (en) 2019-12-19
PL3473621T3 (pl) 2022-01-10
MX2021008988A (es) 2022-05-05
EP3473621A1 (en) 2019-04-24
RS62550B1 (sr) 2021-12-31
CN109311861B (zh) 2021-08-24
AU2017285813A1 (en) 2019-01-17
SG10201911782RA (en) 2020-02-27
RU2019101056A (ru) 2020-07-17
PE20190467A1 (es) 2019-04-04
PT3473621T (pt) 2021-10-04

Similar Documents

Publication Publication Date Title
HUE056428T2 (hu) Kristályos alakú difenilmetán-származék
HK1218372A1 (zh) 修剪箱
ZA201704602B (en) Dihydroindolizinone derivative
EP3227309A4 (en) CRYSTALLINE DIFUCOSYLLACTOSIS
GB201409650D0 (en) Manufacturing methods
IL265445A (en) crystalline forms
IL248772A0 (en) A consequence of cyclohexyl pyridine
GB201419174D0 (en) Crystalline forms
LT3390358T (lt) Kristalinis eravaciklino bis-hidrochloridas
HK1255148A1 (zh) 結晶形式
ZA201700664B (en) Azole benzene derivative and crystalline form thereof
IL261795A (en) Crystalline form
ZA201902553B (en) Crystalline forms
IL251471B (en) A method for producing a derivative of 3- aryloxyquinoline
HK1205853A2 (en) Decorative storage frame
GB201505132D0 (en) Box cutter structure
GB201403323D0 (en) No Title supplied
TWM489062U (en) Tool box structure
TWM490250U (en) Ornamental box
GB201404967D0 (en) X-System 7
GB201404770D0 (en) X-system 7
GB201409595D0 (en) Manufacturing methods
GB201306484D0 (en) Grow pods